The Food and Drug Administration (FDA) approved Eli Lilly’s blockbuster diabetes drug for weight loss management on Wednesday, giving patients another tool and opening the door to potentially much wider use. Formal FDA approval means tirzepatide could be covered by most insurance plans, making it more affordable for millions of patients and likely adding to the massive demand for weight loss drugs like Wegovy and Ozempic. The agency approved Novo Nordisk’s Ozempic for diabetes and Wegovy for obesity in 2017 and 2021, respectively. Both drugs use the active ingredient semaglutide, but Wegovy to date had been the only approved drug on the market for obesity alone. Tirzepatide
Hence then, the article about fda approves blockbuster lilly drug for weight loss was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( FDA approves blockbuster Lilly drug for weight loss )